文献速递甲状腺疾病

2005-2014年英国接受治疗的甲状腺功能减退症的趋势、决定因素及关联

Trends, Determinants, and Associations of Treated Hypothyroidism in the United Kingdom, 2005-2014.
PubMed 文献 · Thyroid · 2019-01-25

患病率存在地理差异,与女性、白人、肥胖比例高及吸烟率低独立相关,且与心房颤动显著相关。

要点

  • 2005-2014年英国治疗甲减患病率从2.3%升至3.5%,2025年预计达4.2%。
  • 患病率地理差异大,伦敦最低1.4%,苏格兰西部群岛最高6.3%。
  • 治疗甲减与女性、白人、肥胖比例高独立相关,与吸烟率负相关。

核心结论

  • 2005-2014年英国治疗甲减患病率增加且存在地理差异,预计未来继续上升。
  • 治疗甲减患病率与女性、白人、肥胖比例高独立相关,与吸烟率负相关。
  • 治疗甲减患病率与心房颤动频率显著相关,但与缺血性心脏病和骨质疏松无关。

研究设计与样本

  • 基于英国国家卫生服务体系和英国国家统计局覆盖全英国的数据进行分析。
  • 主要结局为2005-2014年治疗甲减的患病率趋势,并进行线性趋势预测至2025年。
  • 采用多因素线性回归分析2014年英国237个卫生区域治疗甲减患病率变异决定因素及与其他健康状况的关联。

主要发现

  • 伦敦患病率最低(1.4%),苏格兰西部群岛最高(6.3%),考虑潜在决定因素后差异减弱但未完全消失。
  • 治疗甲减患病率与女性、白人、肥胖比例高独立相关,与吸烟率负相关。
  • 治疗甲减患病率与心房颤动频率显著相关,与缺血性心脏病和骨质疏松无显著关联。

临床怎么用

  • 应关注甲减治疗患病率持续上升的趋势及其对医疗资源的影响。
  • 地理差异提示需针对不同区域制定差异化筛查和管理策略。
  • 甲减与心房颤动的关联提示临床需关注甲减患者的心律失常风险。

局限性

  • 研究为观察性分析,无法确定因果关系。
  • 仅评估接受治疗的甲减,可能低估总体患病率。
  • 治疗趋势的临床效果和成本效益仍有待评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent reports suggest that prescriptions for thyroid hormones have increased. Recent trends in and determinants of the prevalence of treated hypothyroidism across the United Kingdom were therefore analyzed. METHODS: Data covering the whole of the United Kingdom held by the National Health Service and the Office of National Statistics were examined. The main outcome measured was trends in the prevalence of treated hypothyroidism between 2005 and 2014. In addition, linear trend forecasting was performed to estimate projected trends in the prevalence of treated hypothyroidism up to the year 2025. Furthermore, determinants of variation of treated hypothyroidism prevalence across each of the 237 health areas in the United Kingdom in 2014 and its association with other health conditions were explored by multivariate linear regression analyses. RESULTS: The prevalence of treated hypothyroidism increased from 2.3% (1.4 million) to 3.5% (2.2 million) of the total British population between the years 2005 and 2014 and is projected to rise further to 4.2% (2.9 million) by 2025. There was large geographical variation of treated hypothyroidism across the United Kingdom, with London having the lowest (1.4%) and the Western Isles of Scotland having the highest (6.3%) prevalence. This variation was attenuated, but did not completely disappear, after some potential determinants were accounted for. The prevalence of treated hypothyroidism was independently related to health areas, with a higher proportion of individuals who were female, white, and obese, and negatively associated with prevalent cigarette smoking. The prevalence of treated hypothyroidism was significantly associated with the frequency of prevalent atrial fibrillation but not with other major health conditions, including ischemic heart disease and osteoporosis. CONCLUSIONS: Between 2005 and 2014, the prevalence of treated hypothyroidism increased across the United Kingdom, has wide geographical variation, and is likely to increase further for the foreseeable future. Clinical effects and cost-effectiveness of the trend in increasing treatment of hypothyroidism remains to be evaluated.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Razvi S, Korevaar TIM, Taylor P, et al. Trends, Determinants, and Associations of Treated Hypothyroidism in the United Kingdom, 2005-2014. Thyroid. 2019. PMID: 30501570. doi:10.1089/thy.2018.0251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。